PeptideCompareChonluten — EU research guide.
Chonluten is a synthetic tripeptide (Glu-Asp-Gly) from the Khavinson bioregulator series targeting bronchopulmonary tissue broadly, including mucosal and lung-function markers. It is often discussed alongside Bronchogen and Taxorest in Eastern European literature on bronchopulmonary peptide bioregulators, though the three target slightly different aspects of lung tissue.
What is Chonluten?
Chonluten is a synthetic tripeptide (Glu-Asp-Gly) from the Khavinson bioregulator series targeting bronchopulmonary tissue broadly, including mucosal and lung-function markers. It is often discussed alongside Bronchogen and Taxorest in Eastern European literature on bronchopulmonary peptide bioregulators, though the three target slightly different aspects of lung tissue.
What does the research show?
Reported effects center on lung function and mucosal-health markers in claims by the originating research group, summarised in a 2020 review without sample sizes; no primary Chonluten study could be verified. No large independently replicated trials are publicly available as of mid-2026.
EU legal status
Not approved as a medicine anywhere in the EU. Sold by a small number of specialist research vendors for laboratory use only.
Molecular information
Pharmacokinetics
Potency retained over time
Each line is one storage condition: it starts at 100% and declines as potency is lost. Above the dotted 80% line the material is considered reliable — hover the chart for exact values.
⚠ Estimates modelled per component from molecular properties (chain length, cyclisation, oxidation- and deamidation-sensitive residues, light sensitivity). Indicative only — not lab-measured per batch.
Chonluten is not yet in our price comparison
We expand EU supplier coverage every month.
References
- Review by the originating Khavinson group on short peptides in COVID-19. It mentions Chonluten (EDG) only briefly, without sample sizes, and is secondary literature, so it does not on its own establish any clinical effect. Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. Peptides: prospects for use in the treatment of COVID-19. Molecules. 2020;25(19):4389. DOIPubMed 32987757